Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
General Outlook
In simple terms, Geron Corporation has 543.064 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -572.890%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -550.511%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.423% return, is a testament to Geron Corporation's adeptness in optimizing resource deployment. Geron Corporation's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.701%. Furthermore, the proficiency of Geron Corporation in capital utilization is underscored by a remarkable -0.561% return on capital employed.
Stock Prices
Geron Corporation's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.955, while its low point bottomed out at $1.88. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Geron Corporation's stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”